NEW YORK, Nov. 9, 2017 /PRNewswire/ -- Read the full report: https://www.reportlinker.com/p04423650
SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2017, provides an overview of the Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) pipeline landscape.
Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in gene that tells the body to create lipoproteins. It is sympotomized by curvature of spine, muscle weakness, decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.
Report HighlightsGlobal Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 2, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.
Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope- The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders).- The pipeline guide reviews pipeline therapeutics for Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.- The pipeline guide reviews key companies involved in Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) therapeutics and enlists all their major and minor projects.- The pipeline guide evaluates Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.- The pipeline guide reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders)
Reasons to buy- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Find and recognize significant and varied types of therapeutics under development for Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders).- Classify potential new clients or partners in the target demographic.- Develop tactical initiatives by understanding the focus areas of leading companies.- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.- Formulate corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Read the full report: https://www.reportlinker.com/p04423650
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
https://www.reportlinker.com
__________________________Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2017, provides an overview of the Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) pipeline landscape.
Advertisement
Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in gene that tells the body to create lipoproteins. It is sympotomized by curvature of spine, muscle weakness, decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.
Report HighlightsGlobal Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 2, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.
Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope- The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders).- The pipeline guide reviews pipeline therapeutics for Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.- The pipeline guide reviews key companies involved in Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) therapeutics and enlists all their major and minor projects.- The pipeline guide evaluates Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.- The pipeline guide reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders)
Reasons to buy- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Find and recognize significant and varied types of therapeutics under development for Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders).- Classify potential new clients or partners in the target demographic.- Develop tactical initiatives by understanding the focus areas of leading companies.- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.- Formulate corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Adrenomyeloneuropathy Schilder-Addison Complex) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Read the full report: https://www.reportlinker.com/p04423650
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
https://www.reportlinker.com
__________________________Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/adrenoleukodystrophy-adrenomyeloneuropathy-schilder-addison-complex---pipeline-review-h2-2017-300553526.html
SOURCE Reportlinker
